173 - Squabbles Among Friends: Should We Stop Screening for Asymptomatic STIs? And Is Molecular Surveillance for HIV Really Worth It?

Friday, October 13, 2023

1:45 PM – 3:00 PM US ET

Location: 258 ABC

All relevant financial disclosures have been mitigated.

Debate Style Moderator(s)

Wendy Armstrong, MD (she/her/hers)

Professor of Medicine (ID)
Medicine
Emory University School of Medicine
Decatur, GA, United States
Matifadza Hlatshwayo Davis, MD, MPH (she/her/hers)

Director of Health
City of St. Louis Department of Health
St. Louis, MO, United States

Disclosure(s):

Wendy S. Armstrong, MD: No financial relationships to disclose

Matifadza Hlatshwayo Davis, MD, MPH: No financial relationships to disclose

At the conclusion of this session, participants will be able to:

describe the pros and cons of screening for asymptomatic STIs in patients on PrEP and in patients with HIV;
analyze the risks and benefits to using molecular cluster surveillance of HIV

1:45 PM – 2:03 PM US ET

Should We Continue to Screen for Asymptomatic STIs? – PRO
Debate Style Speaker: Karen Wendel, MD (she/her/hers) – Public Health Institute at Denver Health
2:03 PM – 2:21 PM US ET

Should We Continue to Screen for Asymptomatic STIs? – CON
Debate Style Speaker: Hilary Reno, MD, PhD (she/her/hers) – Washington University in St. Louis
2:21 PM – 2:39 PM US ET

Molecular Cluster Surveillance for HIV – Is It Needed? Is It Worth It? – PRO
Debate Style Speaker: Demetre Daskalakis, MD, MPH – White House National Mpox Response
2:39 PM – 2:57 PM US ET

Molecular Cluster Surveillance for HIV – Is It Needed? Is It Worth It? – CON
Debate Style Speaker: Susan J. Little, MD (she/her/hers) – University of California San Diego